September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
11 citations
,
April 2009 in “Pharmacotherapy” Minoxidil can cause deadly skin reaction; monitor patients closely.
July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
23 citations
,
March 2017 in “PTR. Phytotherapy research/Phytotherapy research” Butin is effective in treating vitiligo in mice.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
5 citations
,
April 2023 in “Bioengineering & Translational Medicine” STAR particles are safe, comfortable, and effective for enhancing drug delivery through the skin.
Minoxidil effectively promotes hair growth in seborrheic alopecia.
17 citations
,
March 2004 in “Journal of Investigative Dermatology” Soymetide-4 from soy can prevent hair loss caused by a cancer drug in rats.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
125 citations
,
May 2019 in “Phytomedicine” Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.
TH07 is a topical combination of finasteride, latanoprost, and minoxidil, and shows promise.
A hair tonic with 7.5% daun talok and 2% daun pare promotes hair growth as effectively as minoxidil.
5 citations
,
March 2017 in “Natural Product Research” Researchers found eight natural compounds and essential oils in the Italian plant Bituminaria basaltica, which are typical for its genus and known for bioactivity.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
Acitretin improved monilethrix symptoms temporarily, but they returned after stopping treatment.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
July 2025 in “The Journal of Dermatology” 5% topical minoxidil may help reduce hair loss and increase hair growth in telogen effluvium.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
August 2025 in “Journal of the American Academy of Dermatology” 3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
3 citations
,
May 1979 in “PubMed” March 2022 in “International Journal of Trichology” Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.